[go: up one dir, main page]

SG11202111809XA - Compositions and methods for use of cannabinoids for neuroprotection - Google Patents

Compositions and methods for use of cannabinoids for neuroprotection

Info

Publication number
SG11202111809XA
SG11202111809XA SG11202111809XA SG11202111809XA SG11202111809XA SG 11202111809X A SG11202111809X A SG 11202111809XA SG 11202111809X A SG11202111809X A SG 11202111809XA SG 11202111809X A SG11202111809X A SG 11202111809XA SG 11202111809X A SG11202111809X A SG 11202111809XA
Authority
SG
Singapore
Prior art keywords
cannabinoids
neuroprotection
compositions
methods
Prior art date
Application number
SG11202111809XA
Inventor
Eric Hsu
Ujendra Kumar
Rishi Kumar Somvanshi
Shenglong Zou
Original Assignee
Inmed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmed Pharmaceuticals Inc filed Critical Inmed Pharmaceuticals Inc
Publication of SG11202111809XA publication Critical patent/SG11202111809XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202111809XA 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection SG11202111809XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838216P 2019-04-24 2019-04-24
PCT/CA2020/050547 WO2020215164A1 (en) 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection

Publications (1)

Publication Number Publication Date
SG11202111809XA true SG11202111809XA (en) 2021-11-29

Family

ID=72940570

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111809XA SG11202111809XA (en) 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection

Country Status (11)

Country Link
US (1) US20230043428A1 (en)
EP (1) EP3958856A4 (en)
JP (1) JP7633179B2 (en)
KR (1) KR20220080045A (en)
CN (1) CN114007603A (en)
AU (1) AU2020261515A1 (en)
CA (1) CA3134764A1 (en)
IL (1) IL287536A (en)
MX (1) MX2021012960A (en)
SG (1) SG11202111809XA (en)
WO (1) WO2020215164A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115006404A (en) * 2022-08-09 2022-09-06 昆药集团股份有限公司 Pharmaceutical composition with optic nerve protection effect and application thereof
US20240139272A1 (en) * 2022-10-27 2024-05-02 Kemin Industries, Inc. Use of a spearmint extract for retina neurotrophism
WO2024148117A2 (en) * 2023-01-04 2024-07-11 Florascience Inc. Methods of treating neurodegenerative diseases or conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
AU2011329623A1 (en) * 2010-11-18 2013-07-11 Pier Pharmaceuticals Low dose cannabinoid medicaments
CA3135893C (en) 2014-10-21 2023-11-14 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
MA41299A (en) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc OPHTHALMIC SOLUTIONS FOR THE TREATMENT OF GLAUCOMA AND CONJUNCTIVITIS
US20170266153A1 (en) * 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
CN107405314A (en) * 2015-02-27 2017-11-28 埃布公司 Composition comprising a combination of purified cannabinoids and at least one flavonoid, terpene or mineral
BR112017018316A2 (en) * 2015-02-27 2018-04-17 Ebbu Llc compositions comprising combinations of purified cannabinoids with at least one flavonoid, terpene or mineral
EP3278100B1 (en) * 2015-03-28 2023-06-14 Tecan SP, Inc. Methods and uses comprising solid phase extraction, derivatization with crown ethers, and mass spectrometry
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Dilutable formulations of cannbinoids and processes for their preparation
IL265902B2 (en) 2016-10-11 2024-04-01 Gbs Global Biopharma Inc Complex mixtures containing cannabinoids for the treatment of neurodegenerative diseases
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
JP7323458B2 (en) * 2017-05-08 2023-08-08 インメド ファーマシューティカルズ インコーポレイティド eye drop delivery formulation
WO2018205038A1 (en) 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
US20170348277A1 (en) * 2017-08-02 2017-12-07 Bryan Ray Ruiz Cannabinoid formulation including a vasodilator and ocular delivery of the same

Also Published As

Publication number Publication date
CN114007603A (en) 2022-02-01
MX2021012960A (en) 2022-01-04
KR20220080045A (en) 2022-06-14
CA3134764A1 (en) 2020-10-29
US20230043428A1 (en) 2023-02-09
AU2020261515A1 (en) 2021-11-18
JP7633179B2 (en) 2025-02-19
JP2022530471A (en) 2022-06-29
EP3958856A4 (en) 2023-01-25
EP3958856A1 (en) 2022-03-02
IL287536A (en) 2021-12-01
WO2020215164A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
GB2597163B (en) Cannabinoid compositions and methods of using
EP3790596A4 (en) Oligonucleotide compositions and methods of use thereof
IL287536A (en) Compositions and methods for use of cannabinoids for neuroprotection
EP3893917A4 (en) Il-15 compositions and methods of use thereof
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Compositions and methods of use
IL269590A (en) Methods and compositions for reduction of immunogenicity
GB202105087D0 (en) Microbial compositions and methods of use
GB2597170B (en) Diluents for compositions of cannabinoids and uses thereof
EP3606493A4 (en) Dental cement compositions and methods of use
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
SG11202011041YA (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
IL283850A (en) Cannabis compositions and methods
IL275739A (en) Compositions for cryopreservation and methods of use thereof
IL287797A (en) Oligosaccharide compositions and methods of use
IL283950A (en) Methods and compositions for producing cannabinoids
EP3426238A4 (en) Curcumin-based compositions&methods of use thereof
EP4054514A4 (en) Compositions containing fenchols and methods of use
IL276680A (en) Silica fiber compositions and methods of use
GB202009064D0 (en) Compounds and methods of use
EP3920904A4 (en) Compositions comprising cannabinoids and methods of use thereof
IL285367A (en) Methods and compositions for inhibiting expression of cyp27a1
EP3843721A4 (en) Ophthalmic compositions and methods of use
EP3773497A4 (en) Oxytocin compositions and methods of use
IL291538A (en) Anti-aging compositions and methods of use thereof